Tumor News and Research

RSS

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Celgene International Sàrl announced that investigational data evaluating combination therapy with REVLIMID (lenalidomide) and rituximab in patients with indolent non-Hodgkin’s lymphoma (NHL) were presented during the 51st American Society of Hematology’s annual meeting in New Orleans, LA.

9 Dec 2009

TMZ and small molecule combination appears to lower tumor resistance

University of Florida researchers have found a way to use just a fraction of the normal dosage of a highly toxic, debilitating chemotherapy drug to achieve even better results against colon cancer cells.

9 Dec 2009

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Genzyme Corporation announced today that a Phase 1/2 trial provided early clinical data suggesting that Mozobil (plerixafor injection) in combination with chemotherapy may offer a therapeutic impact on leukemic cells protected in bone marrow.

9 Dec 2009

Transgenomic's SURVEYOR Scan K-RAS mutation detection kit launched

Transgenomic, Inc. announced today the launch of its SURVEYOR Scan K-RAS kit, the first in a family of mutation detection kits the company plans to offer featuring its proprietary SURVEYOR Nuclease and WAVE® HS DHPLC platform. SURVEYOR Scan technology is a novel approach to mutation detection that uses a PCR amplification reaction and hybridization to form heteroduplex DNA molecules in samples with K-RAS mutation.

9 Dec 2009

Multi-institutional study identifies potential treatment target for ovarian cancer

A multi-institutional study has identified a potential personalized treatment target for the most common form of ovarian cancer. In the December 8 issue of Cancer Cell, the research team describes finding that a gene called MAGP2 - not previously associated with any type of cancer - was overexpressed in papillary serous ovarian tumors of patients who died more quickly. They also found evidence suggesting possible mechanisms by which MAGP2 may promote tumor growth.

9 Dec 2009

Neoprobe completes Phase 3 Lymphoseek clinical trial on breast cancer patients

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, has completed a Phase 3 clinical trial of Lymphoseek® (NEO3-05) with positive results.

9 Dec 2009

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced updated clinical data on CAL-101, the Company’s oral, delta selective PI3K inhibitor, presented during two oral presentations at the 51st American Society of Hematology Annual Meeting in New Orleans.

8 Dec 2009

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.

8 Dec 2009

Positive data from Onconova Therapeutics' ON 01910.Na trial for advanced MDS

Onconova Therapeutics, Inc. today announced promising results from two clinical trials in patients with advanced Myelodysplastic Syndrome (MDS) treated with ON 01910.Na. These trials are being conducted at the National Heart, Lung, and Blood Institute (NHLBI) in Bethesda, MD, and St. Vincent’s Comprehensive Cancer Center in New York.

8 Dec 2009

Positive data from ARIAD Pharmaceuticals' ongoing AP24534 study in advanced hematological cancer patients

ARIAD Pharmaceuticals, Inc. today announced positive clinical data from an ongoing Phase 1 study of its investigational, pan-BCR-ABL inhibitor, AP24534, in patients with advanced hematological cancers.

8 Dec 2009

Discovery may lead to new treatments for late-stage breast cancer

Researchers from the Indiana University School of Medicine and colleagues at the University of Texas Southwestern and Case Western University have determined how the protein Mdm2, which is elevated in late-stage cancers, disables genes that suppress the growth of tumors. The finding may lead to the development of new drugs for late stage breast cancer and other difficult to treat malignancies.

8 Dec 2009

Gene positions may offer a new method of cancer diagnosis

Certain genes switch their nuclear position in tumor cells, offering a potential new method of diagnosing cancer, say researchers from the National Cancer Institute. The study by Meaburn et al. will be published online December 7, 2009 (www.jcb.org) and in the December 14, 2009 print issue of the Journal of Cell Biology (JCB).

8 Dec 2009

ImmunoGen's SAR3419 holds hope for B-cell non-Hodgkin’s lymphoma

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of encouraging initial clinical findings with SAR3419 at the American Society of Hematology (ASH) 51st Annual Meeting and Exposition. Among the findings reported were responses to SAR3419 – administered as a single agent – among patients with B-cell non-Hodgkin's lymphoma that is refractory to treatment with rituximab (Rituxan®).

8 Dec 2009

Study: Genetic variations in miRNA pathway may be used to predict secondary tumor in head and neck cancer patients

Eighteen single-point genetic variations indicate risk of recurrence for early-stage head and neck cancer patients and their likelihood of developing a second type of cancer, researchers at The University of Texas M. D. Anderson Cancer Center reported at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference.

8 Dec 2009

Winner of the 2009 Outstanding Investigator Award for Breast Cancer Research

Calling his work "one of the most important findings in breast cancer and health disparities in the last decade," the American Association for Cancer Research (AACR) has named Charles M. Perou, Ph.D. the 2009 Outstanding Investigator Award for Breast Cancer Research, funded by Susan G. Komen for the Cure-.

8 Dec 2009

Turmeric and pepper may play a role in preventing breast cancer

A new study finds that compounds derived from the spices turmeric and pepper could help prevent breast cancer by limiting the growth of stem cells, the small number of cells that fuel a tumor's growth.

8 Dec 2009

SAVI applicator for breast brachytherapy can be an effective therapy for breast cancer

The SAVI™ applicator for breast brachytherapy is a safe, effective therapy for breast cancer, according to a newly published study in a peer-reviewed journal.

8 Dec 2009

Long-chain omega-3 fatty acids can prevent colorectal cancer

Long-chain omega-3 fatty acids, primarily found in fish and seafood, may have a role in colorectal cancer prevention, according to results presented at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference, held Dec. 6-9, 2009, in Houston.

8 Dec 2009

Animal study demonstrates how whole chromosome changes cause cancer

Mayo Clinic researchers have proven the longstanding theory that changes in the number of whole chromosomes -- called aneuploidy -- can cause cancer by eliminating tumor suppressor genes.

8 Dec 2009

Social isolation and stress can raise breast cancer risk

Social isolation and related stress could contribute to human breast cancer susceptibility, research from a rat model designed at the University of Chicago to identify environmental mechanisms contributing to cancer risk shows.

8 Dec 2009

Tumor News and Research

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

TMZ and small molecule combination appears to lower tumor resistance

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Transgenomic's SURVEYOR Scan K-RAS mutation detection kit launched

Multi-institutional study identifies potential treatment target for ovarian cancer

Neoprobe completes Phase 3 Lymphoseek clinical trial on breast cancer patients

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

Positive data from Onconova Therapeutics' ON 01910.Na trial for advanced MDS

Positive data from ARIAD Pharmaceuticals' ongoing AP24534 study in advanced hematological cancer patients

Discovery may lead to new treatments for late-stage breast cancer

Gene positions may offer a new method of cancer diagnosis

ImmunoGen's SAR3419 holds hope for B-cell non-Hodgkin’s lymphoma

Study: Genetic variations in miRNA pathway may be used to predict secondary tumor in head and neck cancer patients

Winner of the 2009 Outstanding Investigator Award for Breast Cancer Research

Turmeric and pepper may play a role in preventing breast cancer

SAVI applicator for breast brachytherapy can be an effective therapy for breast cancer

Long-chain omega-3 fatty acids can prevent colorectal cancer

Animal study demonstrates how whole chromosome changes cause cancer

Social isolation and stress can raise breast cancer risk

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News